24.01.2023 - Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Fate Therapeutics, Inc. (“Fate” or the “Company”) .
23.01.2023 - Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Fate Therapeutics, Inc. (“Fate” or the “Company”) (NASDAQ: FATE) securities between April 2, 2020 and January 5, 2023, inclusive .
07.01.2023 - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Fate Therapeutics, Inc. (“Fate” or “the Company”) (NASDAQ: FATE) for violations of the securities laws. The .
The stock price of Fate Therapeutics, a biopharmaceuticals company focused on oncology and immunology treatments based on natural killer T-Cell programs, has seen a 9% rise over the last five trading days, and we believe the stock will likely continue to rally in the near term.